SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Mimedx Group, Inc. – ‘10-K’ for 12/31/16 – ‘R27’

On:  Wednesday, 3/1/17, at 4:17pm ET   ·   For:  12/31/16   ·   Accession #:  1376339-17-42   ·   File #:  1-35887

Previous ‘10-K’:  ‘10-K/A’ on 2/22/17 for 12/31/15   ·   Next:  ‘10-K’ on 3/17/20 for 12/31/18   ·   Latest:  ‘10-K’ on 2/28/24 for 12/31/23   ·   5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/01/17  Mimedx Group, Inc.                10-K       12/31/16   96:9.2M

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    885K 
 2: EX-3.1      Articles of Incorporation/Organization or Bylaws    HTML     78K 
 3: EX-3.2      Articles of Incorporation/Organization or Bylaws    HTML     91K 
 4: EX-21.1     Subsidiaries List                                   HTML     25K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     27K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     33K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     28K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     28K 
16: R1          Document and Entity Information                     HTML     53K 
17: R2          Consolidated Balance Sheets                         HTML    115K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     46K 
19: R4          Consolidated Statements of Operations               HTML     73K 
20: R5          Consolidated Statements of Stockholders' Equity     HTML    107K 
21: R6          Consolidated Statements of Cash Flows               HTML    113K 
22: R7          Nature of Business                                  HTML     30K 
23: R8          Significant Accounting Policies                     HTML     72K 
24: R9          Liquidity and Capital Resources                     HTML     31K 
25: R10         Acquisition of Stability Inc.                       HTML    164K 
26: R11         Cash Equivalents and Short Term Investments         HTML     28K 
27: R12         Inventories                                         HTML     39K 
28: R13         Property and Equipment                              HTML     44K 
29: R14         Intangible Assets and Royalty Agreement             HTML     70K 
30: R15         Long-Term Debt                                      HTML     32K 
31: R16         Net Income Per Share                                HTML     57K 
32: R17         Equity                                              HTML    144K 
33: R18         Income Taxes                                        HTML     97K 
34: R19         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     46K 
                Investing and Financing Activities                               
35: R20         401k Plan                                           HTML     31K 
36: R21         Related Party Transactions                          HTML     31K 
37: R22         Commitments and Contingencies                       HTML     66K 
38: R23         Quarterly Financial Data (Unaudited)                HTML     78K 
39: R24         Product Revenue Data                                HTML     45K 
40: R25         Subsequent Events                                   HTML     28K 
41: R26         Schedule II - Valuation and Qualifying Accounts     HTML     73K 
42: R27         Significant Accounting Policies (Policies)          HTML    137K 
43: R28         Acquisition of Stability Inc. (Tables)              HTML    154K 
44: R29         Inventories (Tables)                                HTML     40K 
45: R30         Property and Equipment (Tables)                     HTML     41K 
46: R31         Intangible Assets and Royalty Agreement (Tables)    HTML     70K 
47: R32         Net Income Per Share (Tables)                       HTML     68K 
48: R33         Equity (Tables)                                     HTML    142K 
49: R34         Income Taxes (Tables)                               HTML     93K 
50: R35         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     44K 
                Investing and Financing Activities (Tables)                      
51: R36         Commitments and Contingencies (Tables)              HTML     34K 
52: R37         Quarterly Financial Data (Unaudited) (Tables)       HTML     77K 
53: R38         Product Revenue Data (Tables)                       HTML     39K 
54: R39         Nature of Business (Details)                        HTML     27K 
55: R40         Significant Accounting Policies (Details)           HTML     53K 
56: R41         Liquidity and Capital Resources (Details)           HTML     40K 
57: R42         Acquisition of Stability Inc. - Narrative           HTML     74K 
                (Details)                                                        
58: R43         Acquisition of Stability Inc. - Fair Value of       HTML     40K 
                Stock Consideration (Details)                                    
59: R44         Acquisition of Stability Inc. - Preliminarily       HTML    121K 
                Allocation of Purchase Price (Details)                           
60: R45         Acquisition of Stability Inc. - Intangible Assets   HTML     36K 
                Acquired as Part of Acquisition (Details)                        
61: R46         Acquisition of Stability Inc. - Goodwill            HTML     34K 
                Reconciliation (Details)                                         
62: R47         Acquisition of Stability Inc. - Measurement Period  HTML    117K 
                Adjustments (Details)                                            
63: R48         Acquisition of Stability Inc. - Pro Forma           HTML     32K 
                Information (Details)                                            
64: R49         Cash Equivalents and Short Term Investments         HTML     32K 
                (Details)                                                        
65: R50         Inventories (Details)                               HTML     40K 
66: R51         Property and Equipment (Details)                    HTML     54K 
67: R52         Intangible Assets and Royalty Agreement -           HTML     98K 
                Intangible Asssets Activity Summary (Details)                    
68: R53         Intangible Assets and Royalty Agreement -           HTML     29K 
                Narrative (Details)                                              
69: R54         Intangible Assets and Royalty Agreement - Expected  HTML     42K 
                Future Amortization of Intangible Assets (Details)               
70: R55         Long-Term Debt (Details)                            HTML     47K 
71: R56         Net Income Per Share - Computation of Basic and     HTML     50K 
                Dilutive Net Loss per Share (Details)                            
72: R57         Net Income Per Share - Summary of Antidilutive      HTML     38K 
                Securities (Details)                                             
73: R58         Equity - Narrative (Details)                        HTML     82K 
74: R59         Equity - Activity of Stock Options (Details)        HTML     80K 
75: R60         Equity - Exercise Price Ranges (Details)            HTML     77K 
76: R61         Equity - Summary of Unvested Stock Options          HTML     46K 
                (Details)                                                        
77: R62         Equity - Assumptions (Details)                      HTML     45K 
78: R63         Equity - Summary of Restricted Stock Awards         HTML     51K 
                (Details)                                                        
79: R64         Equity - Recognized Stock-Based Compensation        HTML     36K 
                (Details)                                                        
80: R65         Income Taxes - Deferred Tax Assets and Liabilities  HTML     52K 
                (Details)                                                        
81: R66         Income Taxes - Reconciliation of the Federal        HTML     60K 
                Statutory Income Tax (Details)                                   
82: R67         Income Taxes - Schedule of current and deferred     HTML     51K 
                income tax expense (Benefit) (Details)                           
83: R68         Income Taxes - Narrative (Details)                  HTML     51K 
84: R69         Income Taxes - Reconciliation of unrecognized tax   HTML     31K 
                benefits (Details)                                               
85: R70         Supplemental Disclosure of Cash Flow and Non-Cash   HTML     48K 
                Investing and Financing Activities (Details)                     
86: R71         401k Plan (Details)                                 HTML     38K 
87: R72         Related Party Transactions (Details)                HTML     34K 
88: R73         Commitments and Contingencies - Narrative           HTML     56K 
                (Details)                                                        
89: R74         Commitments and Contingencies - Estimated Annual    HTML     38K 
                Lease, Royalty, and Employment Agreement Expenses                
                (Details)                                                        
90: R75         Quarterly Financial Data (Unaudited) (Details)      HTML     46K 
91: R76         Product Revenue Data (Details)                      HTML     37K 
92: R77         Subsequent Events (Details)                         HTML     33K 
93: R78         Schedule II - Valuation and Qualifying Accounts     HTML     42K 
                (Details)                                                        
95: XML         IDEA XML File -- Filing Summary                      XML    163K 
94: EXCEL       IDEA Workbook of Financial Reports                  XLSX    106K 
10: EX-101.INS  XBRL Instance -- mdxg-20161231                       XML   2.32M 
12: EX-101.CAL  XBRL Calculations -- mdxg-20161231_cal               XML    269K 
13: EX-101.DEF  XBRL Definitions -- mdxg-20161231_def                XML    662K 
14: EX-101.LAB  XBRL Labels -- mdxg-20161231_lab                     XML   1.86M 
15: EX-101.PRE  XBRL Presentations -- mdxg-20161231_pre              XML   1.11M 
11: EX-101.SCH  XBRL Schema -- mdxg-20161231                         XSD    167K 
96: ZIP         XBRL Zipped Folder -- 0001376339-17-000042-xbrl      Zip    257K 


‘R27’   —   Significant Accounting Policies (Policies)


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.6.0.2
Significant Accounting Policies (Policies)
12 Months Ended
Accounting Policies [Abstract]  
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported consolidated statements of operations during the reporting period.  Actual results could differ from those estimates.
Principles of Consolidation
Principles of Consolidation
The accompanying financial statements include the accounts of MiMedx Group, Inc. and its wholly-owned subsidiaries MiMedx, Inc., MiMedx Processing Services, LLC (formerly known as SpineMedica, LLC), MiMedx Tissue Services, LLC (formerly known as Surgical Biologics, LLC) and Stability Biologics, LLC (formerly known as Stability Inc.). All significant inter-company balances and transactions have been eliminated.
Segment Reporting
Segment Reporting
ASC 280, “Segment Reporting” requires use of the “management approach” model for segment reporting.  The management approach model is based on the way a company’s management organizes segments within the company for making operating decisions and assessing performance. The Company has determined it has one operating segment.  Disaggregation of the Company’s operating results is impracticable, because the Company’s research and development activities and its assets overlap, and management reviews its business as a single operating segment.  Thus, discrete financial information is not available for more than one operating segment.
Market Concentrations and Credit Risk
Market Concentrations and Credit Risk
The Company places its cash and cash equivalents on deposit with financial institutions in the United States.  In July 2010, the Federal Deposit Insurance Corporation (“FDIC”) increased coverage to $250,000 for substantially all depository accounts.
Cash and Cash Equivalents
Cash and Cash Equivalents
Cash and cash equivalents include cash and FDIC insured certificates of deposit held at various banks with an original maturity of three months or less.
Accounts Receivable
Accounts Receivable
Accounts receivable represent amounts due from customers for which revenue has been recognized.  Generally, the Company does not require collateral or any other security to support its receivables.
The allowance for doubtful accounts is the Company's best estimate of the amount of probable credit losses in the Company's existing receivables. The Company determines the allowance based on factors such as historical collection experience, customers' current creditworthiness, customer concentrations, age of accounts receivable balance and general economic conditions that may affect the customers' ability to pay.
Inventories
Inventories
Inventories are valued at the lower of cost or market, using the first–in, first-out (FIFO) method.  Inventory is tracked through Raw Material, WIP, and Finished Good stages as the product progresses through various production steps and stocking locations. Labor and overhead costs are absorbed through the various production processes up to when the work order closes. Historical yields and normal capacities are utilized in the calculation of production overhead rates.  Reserves for inventory obsolescence are utilized to account for slow-moving inventory as well as inventory no longer needed due to diminished market demand.
Goodwill and Purchased Intangible Assets
Goodwill and Purchased Intangible Assets
Goodwill and purchased intangible assets with indefinite useful lives are not amortized but are tested for impairment at least annually. The Company reviews goodwill and purchased intangible assets with indefinite lives for impairment annually at the beginning of its fourth fiscal quarter and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. Potential impairment indicators include a significant change in the business climate, legal factors, operating performance indicators, competition, and the sale of disposition of a significant portion of the business. The Company first assesses certain qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the Company was less than its carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the Company is less than its carrying amount, then the Company would perform a two-step quantitative impairment testing. In the first step, the Company compares the fair value of the Company to its carrying value. The Company determines the fair value utilizing the market approach. Under the market approach, the Company uses its market capitalization which is calculated by taking the Company’s share price times the number of outstanding shares. If the fair value of the Company exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the Company is less than the carrying value, the Company must perform the second step of the impairment test to measure the amount of impairment loss, if any. In the second step, the Company’s value is allocated to all of the assets and liabilities, including any unrecognized intangible assets, in a hypothetical analysis that calculates the implied fair value of goodwill in the same manner as if the Company was being acquired in a business combination. If the implied fair value of the reporting unit's goodwill is less than the carrying value, the difference is recorded as an impairment loss.
Impairment of Intangible Assets with Finite Lives
Impairment of Intangible Assets with Finite Lives
The Company reviews purchased intangible assets with finite lives for impairment whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable using a two-step impairment test. In step one, we determine the sum of the undiscounted future cash flows of the assets based on management's estimates and compare it to the carrying value of the assets. If the carrying amount is greater than the sum of the undiscounted cash flows, then the asset is impaired and step two is required. In step two, the impairment loss is calculated as the difference between the fair value of the assets and the carrying value of the assets.
Impairment reviews are based on an estimated future cash flow approach that requires significant judgment with respect to future revenue and expense growth rates, selection of appropriate discount rate, asset groupings, and other assumptions and estimates. The Company uses estimates that are consistent with our business plans and a market participant view of the assets being evaluated. Actual results may differ from our estimates.
Property and Equipment
Property and Equipment
Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives, principally three to seven years.  Leasehold improvements are depreciated on a straight-line basis over the lesser of the estimated useful lives or the life of the lease. The Company is party to various lease arrangements for its facility space and equipment. These arrangements include interest, scheduled rent increases and rent holidays which are included in the determination of minimum lease payments when assessing lease classification, and are included in rent expense on a straight line basis over the lease term.
Patent Costs
Patent Costs
The Company incurs certain legal and related costs in connection with patent applications for tissue based products and processes. The Company capitalizes such costs to be amortized over the expected life of the patent to the extent that an economic benefit is anticipated from the resulting patent or alternative future use is available to the Company.
Impairment of Long-lived Assets
Impairment of Long-lived Assets
The Company evaluates the recoverability of its long-lived assets (property and equipment) whenever adverse events or changes in business climate indicate that the expected undiscounted future cash flows from the related assets may be less than previously anticipated.  If the net book value of the related assets exceeds the expected undiscounted future cash flows of the assets, the carrying amount would be reduced to the present value of their expected future cash flows and an impairment loss would be recognized.
Revenue Recognition
Revenue Recognition
The Company sells its products through a combination of a direct sales force, independent stocking distributors and third - party representatives in the U.S. and independent distributors in international markets. The Company recognizes revenue when title to the goods and risk of loss transfers to customers, provided there are no material remaining performance obligations required of the Company or any matters of customer acceptance. The Company records revenues from sales to our independent stocking distributors at the time the product is shipped to the distributor. Our stocking distributors, who sell the products to their customers or sub-distributors, contractually take title to the products and assume all risks of ownership at the time of shipment. Our stocking distributors are obligated to pay us the contractually agreed upon invoice price within specified terms regardless of when, if ever, they sell the products. Our stocking distributors do not have any contractual rights of return or exchange other than for defective product or shipping error; however, in limited situations, we do accept returns or exchanges at our discretion.
Some of the Company’s sales to Government accounts, including the Department of Veterans Affairs, are made through a distributor relationship with AvKARE, which is a veteran-owned General Services Administration Federal Supply Schedule (FSS) contractor. The Company's agreement with AvKARE expires, subject to certain for-cause termination rights, on June 30, 2017. The Company may also elect to terminate the agreement without cause and pay a termination fee to AvKARE as specified in the agreement. Upon termination of the agreement, the parties may mutually agree to extend the agreement or the Company has an obligation to repurchase AvKARE’s remaining inventory, if any, within ninety (90) days in accordance with the terms of the Agreement. At the end of the term, the parties expect AvKARE’s inventory to be minimal, based upon AvKARE's obligation to use commercially reasonable efforts to achieve target sales levels over the remaining term of the agreement.
We continually evaluate new and current customers, including our stocking distributors, for collectability based on various factors including past history with the customer, evaluation of their credit worthiness, and current economic conditions. We only record revenue when collectability is reasonably assured. A portion of the Company’s revenue is generated from inventory maintained at hospitals or physician's offices.
We make estimates of potential future sales returns, discounts and allowances related to current period product revenue and these are reflected as a reduction of revenue in the same period revenue is recognized. We base our estimate for sales returns, discounts and allowances on historical sales and product return information, including historical experience and actual and projected trend information as well as projected sales returns based on estimated usage and contractual arrangements with AvKARE. These estimates have historically been consistent with actual results.
Research and Development Costs
Research and Development Costs
Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies.  These costs are expensed as incurred.
Income Taxes
Income Taxes
The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.
The Company recognizes deferred tax assets to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If we determine that we would be able to realize our deferred tax assets in the future in excess of their net recorded amount, we would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.
The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.
Share-based Compensation
Share-based Compensation
The Company accounts for its share- based compensation plans in accordance with FASB ASC topic 718 “Compensation- Stock compensation”. FASB ASC 718 requires the measurement and recognition of compensation expense for all share-based awards made to employees and directors, including employee stock options, restricted stock and warrants. Under the provisions of FASB ASC 718, and U. S. Securities and Exchange Commission Staff Accounting Bulleting No. 107, share-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense on a straight line basis over the requisite service period of the entire award (generally the vesting period of the award).
Fair Value of Financial Instruments
Fair Value of Financial Instruments
The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature and type of these instruments. These financial instruments include cash and cash equivalents, accounts receivable, short term investments, accounts payable and accrued expenses. The carrying cost of the Company’s investments also reflects their fair values due to the type of these investments and the fair value of capital leases approximates their carrying value based upon current rates available to the Company.
Fair Value Measurements
Fair Value Measurements
The Company records certain financial instruments at fair value, including: cash equivalents, short term investments and investments.  The Company may make an irrevocable election to measure other financial instruments at fair value on an instrument-by-instrument basis; although as of December 31, 2016, the Company has not chosen to make any such elections.  Fair value financial instruments are recorded in accordance with the fair value measurement framework.
The Company also measures certain non-financial assets at fair value on a non-recurring basis.  These non-recurring valuations include evaluating assets such as long-lived assets, and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group, and accounting for business combinations.  The Company uses the fair value measurement framework to value these assets and reports these fair values in the periods in which they are recorded or written down.
The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels.  These levels from highest to lowest priority are as follows:
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;
Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.
The determination of fair value and the assessment of a measurement’s placement within the hierarchy require judgment. Level 3 valuations often involve a higher degree of judgment and complexity.  Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions.  Management’s assumptions could vary depending on the asset or liability valued and the valuation method used.  Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods.  The Company may also engage external advisors to assist it in determining fair value, as appropriate.
In connection with the acquisition of Stablity, the Company recorded a liability related to the Earn-Out portion of the purchase consideration. See Note 4, Acquisition, for further discussion of the Earn-Out liability. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability will be evaluated each reporting period and changes in its fair value will be included in the Company’s results of operations. The fair value of the Earn-Out liability was calculated using a discount rate, approximating the pre-tax cost of debt and corroborated by Monte Carlo simulation, which was then applied to estimated earn out payments. To determine the fair value of the Earn-Out liability, management evaluates assumptions that require significant judgment. Changes in certain inputs to the valuation model, including the Company’s estimate of future revenues, can have a significant impact on the estimated fair value. The fair value recorded for the Earn-Out liability may vary significantly from period to period. This variability may result in the actual liability for a period either above or below the estimates recorded in the Company’s Consolidated Financial Statements, resulting in significant fluctuations in results of operations as a result of the corresponding non-cash gain or loss recorded.
Although the Company believes that the recorded fair value of its financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
The Company considers the applicability and impact of all Accounting Standards Updates ("ASUs"). In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU 2014-09, “Revenue Recognition - Revenue from Contracts with Customers” (ASU 2014-09) that requires companies to recognize revenue when a customer obtains control rather than when companies have transferred substantially all risks and rewards of a good or service. This update is effective for annual reporting periods beginning on or after December 15, 2017 and interim periods therein and requires expanded disclosures. The Company is currently assessing the impact the adoption of ASU 2014-09 will have on its consolidated financial statements.
In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments, that eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. ASU 2015-16 is effective for public companies for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company has adopted this standard in the first quarter of 2016 and its application is shown in Note 4.
In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company has adopted this standard, prospectively, at the beginning of the fourth quarter 2015 to simplify reporting with the release of the valuation allowance as disclosed in Note 12. Prior periods were not retrospectively adjusted.
In February 2016, the FASB issued Accounting Standards Update ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases.  ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years.  The guidance may be adopted prospectively or retrospectively and early adoption is permitted.  The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, "Compensation - Stock Compensation (Topic 718)". The standard is
intended to simplify several areas of accounting for share - based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. This ASU is effective for fiscal years beginning after December 15, 2016. The Company is currently assessing the impact the adoption of ASU 2016-09 will have on its consolidated financial statements. As of December 31, 2016, the Company does not have any remaining deferred tax assets that will result in an increase to equity upon realization. See Note 12.

In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company is currently assessing the impact of the adoption of ASU 2016-15 will have on its consolidated financial statements.
All other ASUs issued and not yet effective for the year ended December 31, 2016, and through the date of this report, were assessed and determined to be either not applicable or are expected to have minimal impact on the Company's financial position or results of operations.
Acquisitions
The acquisition was accounted for as a purchase business combination as defined by FASB Topic 805 - "Business Combinations". The fair value of the contingent consideration is measured as a Level 3 instrument. The contingent consideration liability is recorded at fair value on the acquisition date. Increases or decreases in the fair value of contingent consideration can result from changes in anticipated revenue levels and changes in assumed discount periods and rates. As the fair value measured is based on significant inputs that are not observable in the market, they are categorized as Level 3. The income valuation approach was applied in determining the fair value of the contingent consideration using a discounted cash flow valuation technique with significant unobservable inputs comprised of projected sales and certain expenses. The values assigned to intangible assets are subject to amortization.
Net Income Per Share
Net Income Per Share
Basic net income per common share is computed using the weighted-average number of common shares outstanding during the period.  Diluted net income per common share is computed using the weighted-average number of common and dilutive common equivalent shares from stock options, warrants and restricted stock using the treasury stock method.

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
12/15/18
12/15/17
6/30/1710-Q,  8-K
Filed on:3/1/17
For Period end:12/31/165
12/15/16
12/15/15
 List all Filings 


5 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/17/20  Mimedx Group, Inc.                S-8        12/17/20    5:422K                                   Donnelley … Solutions/FA
11/04/20  Mimedx Group, Inc.                10-Q        9/30/20   79:7.4M
11/02/20  Mimedx Group, Inc.                8-A12B                 1:37K
 8/04/20  Mimedx Group, Inc.                10-Q        6/30/20   71:5.9M
 3/20/17  SEC                               UPLOAD9/28/17    1:173K Mimedx Group, Inc.
Top
Filing Submission 0001376339-17-000042   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 8:50:36.1am ET